Literature DB >> 20844480

Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins.

N Lycke1, M Bemark.   

Abstract

The ultimate goal for vaccination is to stimulate protective immunological memory. Protection against infectious diseases not only relies on the magnitude of the humoral immune response, but more importantly on the quality and longevity of it. Adjuvants are critical components of most non-living vaccines. Although little attention has been given to qualitative aspects of the choice of vaccine adjuvant, emerging data demonstrate that this function may be central to vaccine efficacy. In this review we describe efforts to understand more about how adjuvants influence qualitative aspects of memory development. We describe recent advances in understanding how vaccines induce long-lived plasma and memory B cells, and focus our presentation on the germinal center reaction. As mucosal vaccination requires powerful adjuvants, we have devoted much attention to the adenosine diphosphate (ADP)-ribosylating cholera toxin and the CTA1-DD adjuvants as examples of how mucosal adjuvants can influence induction of long-term memory.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844480     DOI: 10.1038/mi.2010.54

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  30 in total

Review 1.  Mechanisms of Cholera Toxin in the Modulation of TH17 Responses.

Authors:  Hsing-Chuan Tsai; Reen Wu
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

2.  Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice.

Authors:  A Lemke; M Kraft; K Roth; R Riedel; D Lammerding; A E Hauser
Journal:  Mucosal Immunol       Date:  2015-05-06       Impact factor: 7.313

Review 3.  The regulation of gut mucosal IgA B-cell responses: recent developments.

Authors:  N Y Lycke; M Bemark
Journal:  Mucosal Immunol       Date:  2017-07-26       Impact factor: 7.313

Review 4.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

Review 5.  Vaccine approaches for multidrug resistant Gram negative infections.

Authors:  Brian Campfield; Kong Chen; Jay K Kolls
Journal:  Curr Opin Immunol       Date:  2014-03-15       Impact factor: 7.486

Review 6.  Murine models for mucosal tolerance in allergy.

Authors:  Ursula Smole; Irma Schabussova; Winfried F Pickl; Ursula Wiedermann
Journal:  Semin Immunol       Date:  2017-08-12       Impact factor: 11.130

7.  Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually.

Authors:  Justin L Spinner; Hardeep S Oberoi; Yvonne M Yorgensen; Danielle S Poirier; David J Burkhart; Martin Plante; Jay T Evans
Journal:  Vaccine       Date:  2015-09-21       Impact factor: 3.641

8.  Cellular Dynamics of Memory B Cell Populations: IgM+ and IgG+ Memory B Cells Persist Indefinitely as Quiescent Cells.

Authors:  Derek D Jones; Joel R Wilmore; David Allman
Journal:  J Immunol       Date:  2015-10-05       Impact factor: 5.422

Review 9.  Translational Mini-Review Series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell developmental pathways and lineage phenotypes.

Authors:  M Bemark; J Holmqvist; J Abrahamsson; K Mellgren
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 10.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.